Drug Trial Radar · NCT07084961
A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Aug 5, 2025
Primary completion
Sep 11, 2025
Study completion Sep 16, 2025
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 39 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.
Conditions
- Healthy Adult Male Subjects
Interventions
TS-172Drug
Oral administration of TS-172 20 mg immediately before meal
TS-172Drug
Oral administration of TS-172 20 mg immediately after meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinaly excretion of phosphorusTime frame: Up to 3 days postdose during each period
- Urinaly excretion of sodiumTime frame: Up to 3 days postdose during each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.